Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 6, 2015, Pages

  Kim, Sung Min ^a   Woodhall, Mark R ^b   Kim, Ji Sun ^a   Kim, Seong Joon ^a   Park, Kyung Seok ^a,c   Vincent, Angela ^b   Lee, Kwang Woo ^a   Waters, Patrick ^b  

^a Seoul National University   (South Korea)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PREDNISOLONE; PREDNISONE; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE TRANSVERSE MYELITIS; ADULT; AGED; ARTICLE; ASSAY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY DEMYELINATING DISEASE; LIVE CELL BASED ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; OPTIC NEURITIS; OUTCOME ASSESSMENT; PARAPLEGIA; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; SOFT TISSUE;

EID: 84952923110     PISSN: 23327812     EISSN: None     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000163     Document Type: Article

References (23)

1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
3. de Seze J, Debouverie M, Zephir H, et al. Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol 2007;64:1426-1432.
4. Shams P, Plant G. Optic neuritis: a review. Int MS J 2009; 16:82-89.
5. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59:499-505.
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
7. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
8. Kim SM, Waters P, Woodhall M, et al. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Mult Scler 2013;19: 1060-1067.
9. Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 2014;10:493-506.
10. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-481.
11. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276-283.
12. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013;9:455-461.
13. Waters P, Woodhall M, O'Connor KC, et al. MOG cellbased assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89. doi: 10.1212/NXI.0000000000000089.
14. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288.
15. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581-588.
16. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009;73:1914-1922.
17. Kim SM, Waters P, Woodhall M, et al. Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. BMC Neurol 2014;14:93. doi: 10.1186/ 1471-2377-14-93.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
19. Horowitz AL, Kaplan RD, Grewe G, White RT, Salberg LM. The ovoid lesion: a new MR observation in patients with multiple sclerosis. AJNR Am J Neuroradiol 1989;10:303-305.
20. Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult Scler Epub 2015 Feb 6.
21. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66:833-842.
22. Lalive PH, Hausler MG, Maurey H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011;17:297-302.
23. Young NP, Weinshenker BG, Lucchinetti CF. Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol 2008;28:84-94.